Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
Clinical trial NCT06542549 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06542549
- Sponsor
- Anhui Provincial Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-01
- Primary completion
- 2027-10-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.